Michel Vounatsos (Credit: World Economic Forum/Valeriano Di Domenico)
September 9, 2021 12:35 PM EDTUpdated September 10, 02:47 PM
Pharma

Bio­gen CEO Vounatsos laments 'con­fu­sion' and 'mis­in­for­ma­tion' lead­ing to chal­lenges with Aduhelm up­take

Zachary Brennan

Senior Editor

Bio­gen CEO Michel Vounatsos on Thurs­day ad­mit­ted the com­pa­ny is ex­pe­ri­enc­ing some “near term chal­lenges” in launch­ing its con­tro­ver­sial new Alzheimer’s drug, a lit­tle more …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. de­fends HHS staff cuts, re­or­ga­ni­za­tion plans in House, Sen­ate hear­ings

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

RFK Jr. says his opin­ions of vac­cines are ‘ir­rel­e­vant.’ For­mer FDA chief Califf dis­agrees

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

Sanofi touts $20B in­vest­ment in US over five years

A service from the Financial Times